Article

Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptor

2024-02-01

Abstract excerpt

Myeloid cells are prevalent in solid cancers, but they frequently exhibit a pro-tumor phenotype, hindering cancer immunotherapy. Their abundance makes engineered myeloid cell therapy an intriguing approach to tackle challenges posed by solid cancers, such as tumor trafficking and infiltration along with tumor cell heterogenicity and immunosuppressive tumor microenvironment (TME). Solid cancers often upregulate the...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bb73db4c-40e8-53b7-a138-326718148133
DOI: 10.1101/2024.01.29.577873

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptorDOI 10.1101/2024.01.29.577873Read

Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.Semantic proximity Read

Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophages.Semantic proximity Read

PD-L1 blockade restores CAR T cell activity through IFNγ-regulation of CD163+ macrophagesSemantic proximity Read

CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentationSemantic proximity Read

A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapySemantic proximity Read

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advancesSemantic proximity Read

A Novel Chimeric Antigen Receptor (CAR) - Strategy to Target EGFR<sup>VIII</sup>-Mutated Glioblastoma Cells via MacrophagesSemantic proximity Read

Chimeric antigen receptors that trigger phagocytosisSemantic proximity Read

CAR-Engineered Human Hematopoietic Stem Cell Macrophages Control Solid TumorsSemantic proximity Read

PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivoSemantic proximity Read

A novel Chimeric Antigen Receptor (CAR) - strategy to target EGFRVIII-mutated glioblastoma cells via macrophages.Semantic proximity Read

CAR-MACROPHAGES ACTIVATE ANTI TUMOR T CELLS IN THE ABSENCE OF PHAGOCYTOSISSemantic proximity Read